SG11202010830WA - Methods of treating phenylketonuria - Google Patents

Methods of treating phenylketonuria

Info

Publication number
SG11202010830WA
SG11202010830WA SG11202010830WA SG11202010830WA SG11202010830WA SG 11202010830W A SG11202010830W A SG 11202010830WA SG 11202010830W A SG11202010830W A SG 11202010830WA SG 11202010830W A SG11202010830W A SG 11202010830WA SG 11202010830W A SG11202010830W A SG 11202010830WA
Authority
SG
Singapore
Prior art keywords
methods
treating phenylketonuria
phenylketonuria
treating
Prior art date
Application number
SG11202010830WA
Inventor
Geoffrey Berguig
Rajeev Mahimkar
Hassib Akeefe
Peter Colosi
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of SG11202010830WA publication Critical patent/SG11202010830WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16001—Phenylalanine 4-monooxygenase (1.14.16.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
SG11202010830WA 2018-05-09 2019-05-08 Methods of treating phenylketonuria SG11202010830WA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862669292P 2018-05-09 2018-05-09
US201862755207P 2018-11-02 2018-11-02
US201962802608P 2019-02-07 2019-02-07
US201962819414P 2019-03-15 2019-03-15
PCT/US2019/031252 WO2019217513A2 (en) 2018-05-09 2019-05-08 Methods of treating phenylketonuria

Publications (1)

Publication Number Publication Date
SG11202010830WA true SG11202010830WA (en) 2020-11-27

Family

ID=66794083

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010830WA SG11202010830WA (en) 2018-05-09 2019-05-08 Methods of treating phenylketonuria

Country Status (15)

Country Link
US (1) US11739345B2 (en)
EP (1) EP3790627A2 (en)
JP (1) JP2021522811A (en)
KR (1) KR20210008501A (en)
CN (1) CN113164762A (en)
AU (1) AU2019265560A1 (en)
BR (1) BR112020022722A8 (en)
CA (1) CA3099704A1 (en)
CL (1) CL2020002892A1 (en)
MX (1) MX2020011937A (en)
PE (1) PE20210112A1 (en)
PH (1) PH12020551863A1 (en)
SG (1) SG11202010830WA (en)
TW (1) TW202016314A (en)
WO (1) WO2019217513A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL305149A (en) 2016-07-26 2023-10-01 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
WO2019070674A2 (en) * 2017-10-02 2019-04-11 American Gene Technologies International Inc. Vectors with promoter and enhancer combinations for treating phenylketonuria
JP7423521B2 (en) 2017-11-22 2024-01-29 モダーナティエックス・インコーポレイテッド Polynucleotide encoding phenylalanine hydroxylase for the treatment of phenylketonuria
TW202005978A (en) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 Novel liver targeting adeno-associated viral vectors
JP2023510392A (en) * 2020-01-16 2023-03-13 武田薬品工業株式会社 Adeno-associated virus-based gene therapy for phenylketonuria
AR122409A1 (en) 2020-04-03 2022-09-07 Biomarin Pharm Inc TREATMENT OF PHENYLKETONURIA WITH AAV AND THERAPEUTIC FORMULATIONS
WO2021207415A1 (en) * 2020-04-07 2021-10-14 The Curators Of The University Of Missouri CpG-FREE ITRs FOR AAV GENE THERAPY
WO2021252952A1 (en) * 2020-06-11 2021-12-16 Sangamo Therapeutics, Inc. Methods and compositions for expressing phenylalanine hydroxylase
KR20230078805A (en) 2020-11-02 2023-06-02 바이오마린 파머수티컬 인크. Enrichment process of adeno-associated virus
US20220160728A1 (en) * 2020-11-05 2022-05-26 Homology Medicines, Inc. Gene therapy methods
WO2023034989A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034990A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034994A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034980A1 (en) 2021-09-03 2023-03-09 Bomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034997A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034996A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
CN115772503B (en) * 2022-08-16 2023-10-17 广东省南山医药创新研究院 Gene modified cell medicine for expressing PAH and preparation method and application thereof
WO2024064863A2 (en) 2022-09-22 2024-03-28 Biomarin Pharmaceutical Inc. Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
WO2024064856A1 (en) 2022-09-22 2024-03-28 Biomarin Pharmaceutical Inc. Treatment of cardiomyopathy with aav gene therapy vectors
CN115896135B (en) * 2022-11-02 2024-03-01 苏州诺洁贝生物技术有限公司 Optimized PAH gene and expression cassette and use thereof
CN116656740A (en) * 2023-05-30 2023-08-29 浙江大学 Adeno-associated virus gene therapy vector and application thereof in preparation of medicament for treating phenylketonuria

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US955734A (en) 1909-04-26 1910-04-19 Joseph Wolkerstorfer Display-rack.
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
ATE78293T1 (en) 1983-05-27 1992-08-15 Texas A & M Univ Sys METHOD OF GENERATING A RECOMBINANT BACULOVIRUS EXPRESSION VECTOR.
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
RU2273645C9 (en) 1994-08-17 2006-11-27 Дзе Рокефеллер Юниверсити Obesity polypeptide (ob) (variants), its analogue (variants), and fused protein (variants), nucleic acid isolated molecule, dna molecule, cloning recombinant vector, expression recombinant vector, pharmaceutical composition, monoclonal and polyclonal antibody
WO1998010088A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6521225B1 (en) 1996-09-06 2003-02-18 Chiron Corporation AAV vectors
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
TR200003087T2 (en) 1998-04-21 2001-02-21 Micromet Ag New CD19 X CD3 Specific polypeptides and their use
US7056502B2 (en) 2000-04-28 2006-06-06 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
JPWO2003033710A1 (en) 2001-10-16 2005-02-03 独立行政法人産業技術総合研究所 Novel N-acetylglucosamine transferase, nucleic acid encoding the same, antibody thereto, and use for cancer or tumor diagnosis
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
CN105671005B (en) 2001-11-13 2020-09-15 宾夕法尼亚大学托管会 Methods for detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified
EP3339430A1 (en) 2001-12-17 2018-06-27 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses thereof
AU2003212708A1 (en) 2002-03-05 2003-09-16 Stichting Voor De Technische Wetenschappen Baculovirus expression system
US20030198620A1 (en) * 2002-04-16 2003-10-23 Keiya Ozawa Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions
US20040142416A1 (en) * 2002-04-30 2004-07-22 Laipis Philip J. Treatment for phenylketonuria
DK2292779T3 (en) 2003-09-30 2017-02-27 Univ Pennsylvania ADENOASS-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME AND APPLICATIONS THEREOF
JP5184783B2 (en) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド Tetrahydrobiopterin and method for producing tetrahydrobiopterin analog
EP1771571A2 (en) 2004-07-30 2007-04-11 Targeted Genetics Corporation Recombinant aav based vaccine methods
JP2008520574A (en) 2004-11-17 2008-06-19 バイオマリン ファーマシューティカル インコーポレイテッド Tetrahydrobiopterin stable tablet formulation
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
CN101711164B (en) 2007-01-18 2014-06-04 密苏里-哥伦比亚大学 Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma
AR066354A1 (en) * 2007-05-01 2009-08-12 Genzyme Corp SYSTEMATIC THERAPY WITH INSULIN TYPE GROWTH FACTOR-1 REDUCES DIABETIC PERIPHERAL NEUROPATHY AND IMPROVES RENAL FUNCTION IN DIABETIC NEPHROPATIA
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
JP2011508781A (en) 2008-01-07 2011-03-17 ビオマリン プハルマセウトイカル インコーポレイテッド Method for the synthesis of tetrahydrobiopterin
ES2579231T3 (en) 2008-01-15 2016-08-08 Abbvie Inc Enhanced mammalian expression vectors and uses thereof
US7943379B2 (en) 2008-04-30 2011-05-17 Nationwide Children's Hospital, Inc. Production of rAAV in vero cells using particular adenovirus helpers
US20110201022A1 (en) 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
PL2337849T3 (en) 2008-09-15 2018-11-30 Uniqure Biopharma B.V. Factor ix polypeptide mutant, its uses and a method for its production
JP6174318B2 (en) 2009-04-30 2017-08-02 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Composition for targeting conducting airway cells comprising an adeno-associated virus construct
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
EP3284821B1 (en) 2010-03-23 2022-01-05 Precigen, Inc. Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
CN102869779A (en) 2010-03-29 2013-01-09 宾夕法尼亚大学托管会 Pharmacologically induced transgene ablation system
FR2977562B1 (en) 2011-07-06 2016-12-23 Gaztransport Et Technigaz SEALED AND THERMALLY INSULATING TANK INTEGRATED IN A CARRIER STRUCTURE
MX367100B (en) 2012-02-17 2019-08-05 The Children´S Hospital Of Philadelphia Aav vector compositions and methods for gene transfer to cells, organs and tissues.
CN108949772A (en) 2012-04-02 2018-12-07 现代泰克斯公司 For generating the modification polynucleotides of biological agent relevant to human diseases and protein
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
CA2901328C (en) 2013-03-15 2023-08-01 The Trustees Of The University Of Pennsylvania Compositions and methods for treating mps1
PE20160769A1 (en) 2013-09-12 2016-08-12 Biomarin Pharm Inc VECTORS OF ADENO-ASSOCIATED VIRUS FACTOR VIII
CA3182790A1 (en) 2013-10-11 2015-04-16 Massachusetts Eye & Ear Infirmary Ancestral adeno-associated virus sequences and uses thereof
EA201992208A1 (en) * 2013-10-22 2020-07-31 Транслейт Био, Инк. TREATMENT OF PHENYLKETONURIA USING mRNA
DK3116900T3 (en) 2014-03-09 2020-09-28 Univ Pennsylvania COMPOSITIONS THAT CAN BE USED TO TREAT ORNITHIN TRANSCARBAMYLASE (OTC) DEFECT
EP2960336A1 (en) 2014-06-27 2015-12-30 Genethon Efficient systemic treatment of dystrophic muscle pathologies
CN114344275A (en) * 2014-07-02 2022-04-15 川斯勒佰尔公司 Encapsulation of messenger RNA
EP3194600B1 (en) 2014-07-26 2019-08-28 Consiglio Nazionale Delle Ricerche Compositions and methods for treatment of muscular dystrophy
PT3198018T (en) 2014-09-24 2021-02-24 Hope City Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
GB201507842D0 (en) 2015-05-07 2015-06-17 New Royal Holloway & Bedford Production of large-sized microdystrophins in an AAV-based vector configuration
PL3872085T3 (en) 2015-07-30 2023-06-05 Massachusetts Eye & Ear Infirmary Ancestral aav sequences and uses thereof
AU2016326602A1 (en) 2015-09-24 2018-03-29 Biomarin Pharmaceutical Inc. Adeno-associated virus factor VIII vectors, associated viral particles and therapeutic formulations comprising the same
WO2017066764A2 (en) 2015-10-16 2017-04-20 William Marsh Rice University Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
BR112018008519A2 (en) 2015-10-28 2018-11-06 Sangamo Therapeutics Inc liver-specific constructs, factor viii expression cassettes and methods of use thereof
PE20231949A1 (en) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTS OF FACTOR VIII REDUCED WITH CpG, COMPOSITIONS AND METHODS AND USES FOR THE TREATMENT OF HEMOSTASY DISORDERS
IL305149A (en) 2016-07-26 2023-10-01 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
JP2019537578A (en) 2016-11-04 2019-12-26 バクスアルタ インコーポレイテッド Adeno-associated virus preparation
EP3562494A4 (en) * 2016-12-30 2020-08-19 The Trustees Of The University Of Pennsylvania Gene therapy for treating phenylketonuria
EA202091844A1 (en) 2018-02-01 2021-02-03 Хомолоджи Медисинс, Инк. COMPOSITIONS OF ADENO-ASSOCIATED VIRUSES FOR PAH GENE TRANSFER AND METHODS OF THEIR APPLICATION
US10610606B2 (en) * 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
BR112020023159A2 (en) 2018-05-14 2021-02-02 Biomarin Pharmaceutical Inc. method for improving symptoms of a genetic disorder in a young individual, use of a therapeutic aav virus, composition, method for reducing bleeding time, use of a therapeutically effective amount of a therapeutic aav virus and method for increasing protein expression
TW202005978A (en) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 Novel liver targeting adeno-associated viral vectors
CA3107462A1 (en) 2018-07-24 2020-01-30 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
AR118734A1 (en) 2019-04-19 2021-10-27 Regenxbio Inc FORMULATIONS AND METHODS OF ADENO-ASSOCIATED VIRUS VECTORS
WO2020232044A1 (en) 2019-05-14 2020-11-19 Biomarin Pharmaceutical Inc. Methods of redosing gene therapy vectors
AR122409A1 (en) 2020-04-03 2022-09-07 Biomarin Pharm Inc TREATMENT OF PHENYLKETONURIA WITH AAV AND THERAPEUTIC FORMULATIONS

Also Published As

Publication number Publication date
TW202016314A (en) 2020-05-01
CN113164762A (en) 2021-07-23
US11739345B2 (en) 2023-08-29
MX2020011937A (en) 2021-01-29
PH12020551863A1 (en) 2021-07-19
CL2020002892A1 (en) 2021-05-07
KR20210008501A (en) 2021-01-22
BR112020022722A2 (en) 2021-02-02
US20190376081A1 (en) 2019-12-12
WO2019217513A3 (en) 2019-12-19
EP3790627A2 (en) 2021-03-17
PE20210112A1 (en) 2021-01-19
AU2019265560A1 (en) 2020-11-26
BR112020022722A8 (en) 2022-01-18
WO2019217513A2 (en) 2019-11-14
JP2021522811A (en) 2021-09-02
CA3099704A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
SG11202010830WA (en) Methods of treating phenylketonuria
IL269026A (en) Methods of treating tumor
ZA202006746B (en) Methods of treatment
IL269620A (en) Compositions and methods for treating phenylketonuria
EP3710102A4 (en) Methods of treating glioblastoma
GB201804514D0 (en) Treatment of pyroptosis
ZA201903873B (en) Methods of treating cochlear synaptopathy
HK1245657A1 (en) Method of preventing or treating hearing loss
IL272092A (en) Methods of treating behavior alterations
EP3634422A4 (en) Methods of treating leukodystrophies
ZA201907401B (en) Treatment of adipocytes
GB201706406D0 (en) Method of treatment
GB201815588D0 (en) Method of treatment
GB201804515D0 (en) Treatment of necroptosis
EP3491129A4 (en) Methods of treating osmidrosis
GB201602802D0 (en) Method of treatment
EP3655418A4 (en) Methods of treating glioblastoma
PL3292226T3 (en) Method for the treatment of iron-containing sludge
SG11202105877YA (en) Method of treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
ZA201903931B (en) Method of treating meat
SG11201710199PA (en) Methods of treating multiple sclerosis
GB201512139D0 (en) Methods of treatment
IL290983A (en) Methods of treatment
ZA201906319B (en) Methods of treating depression